Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the Trips Agreement: BIBLIOGRAPHY

Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the Trips Agreement
(2002; 77 pages) [Spanish]

Table of Contents

THE SOUTH CENTRE
FOREWORD
EXECUTIVE SUMMARY
INTRODUCTION
I. DATA REQUIRED FOR THE REGISTRATION OF PHARMACEUTICALS
II. THE RATIONALE FOR DATA PROTECTION
	A. Approaches to Data Protection
	B. National Practices before TRIPS
III. CONDITIONS OF PROTECTION UNDER TRIPS
	A. Protection of test data under the TRIPS Agreement
	B. The Article 39.3 conditions of protection
		1. Data necessary for marketing approval
		2. Protected data
		3. Undisclosed data
		4. New chemical entities
		5. Considerable effort (investment)
IV. NON-DISCLOSURE OBLIGATION
V. PROSCRIBED ACTS OF UNFAIR COMMERCIAL USE
	A. The TRIPS Agreement text
		1. "Unfair"
		2. "Commercial"
		3. "Use"
		4. Analysing "Unfair Commercial Use"
	B. National case law
VI. MEANS OF PROTECTION AGAINST UNFAIR COMMERCIAL USE
VII. THE EXCLUSIVITY APPROACH
VIII. THE HISTORY OF THE TRIPS NEGOTIATIONS
IX. CONCLUSIONS
ANNEX I. EXCLUSIVE USE OF DATA AND COMPENSATION UNDER THE U.S. FEDERAL INSECTICIDE, FUNGICIDE AND RODENTICIDE ACT (FIFRA)
BIBLIOGRAPHY
BACK COVER

BIBLIOGRAPHY

Beier, Friedrich-Karl and Schricker, Gerhard (1989), GATT or WIPO - New ways in the international protection of intellectual property, VCH, Winheim.

Coleman, Allison, (1992), The legal protection of trade secrets, Sweet & Maxwell, London.

Cook, Trevor, (2000). Special Report: The protection of regulatory data in the pharmaceutical and other sectors, Sweet & Maxwell, London.

Correa, Carlos, (2000) "Implementing national public health policies in the framework of the WTO Agreements" (2000), Journal of World Trade, vol. 34, No. 5, September.

Correa, Carlos and Yusuf, Abdulqawi (1998), Intellectual property and international trade. The TRIPS Agreement, Kluwer Law International, London-Cambridge.

Dodds-Smith, Ian, (2000), "Data protection and abridged applications for marketing authorisation in the pharmaceutical industry", Goldberg, Richard and Lonbay, Julian, (Eds.), Pharmaceutical Medicine. Biotechnology, and European Law, Cambridge University Press, Cambridge.

Dukes, M.N. Graham, (1996), "Drug regulation and the tradition of secrecy", International Journal of Risk & Safety in Medicine, No. 9.

Dukes, M.N. Graham, (1977), "The moments of truth", Side "Effects of Drugs Annual, 1, Wxcerpta Medica, Amsterdam and Oxford.

Engelberg, Alfred (2001) "Data Exclusivity Under Article 39.3 of TRIPS: Does Current US Law Comply?", Working Paper, October 22.

European Union (EU), (2001), Questions on TRIPs and data exclusivity. An EU contribution, Brussels.

Font Segura, Albert, (1999), La protección internacional del secreto empresarial, Colección Estudios Internacionales, Ed. EUROLEX, No. XXXI, Madrid.

Gambardella, Alfonso, (1995), Science and innovation. The Us pharmaceutical industry during the 1980s, Cambridge University Press. Cambridge.

Gervais, Daniel (1998), The TRIPS Agreement. Drafting history and analysis, Sweet & Maxwell, London.

Henning-Bodewig, Frauke, (1999), "International protection against unfair competition -Art. 10bis Paris Convention, TRIPS and WIPO Model Provisions", IIC, vol.30, No.2.

International Intellectual Property Institute (IIPI) (2000), Patent protection and access to HIV/AIDS pharmaceuticals in Sub-Saharan Africa, Washington D.C.

Jones, Nigel and Nittenberg, Ronald, (1998/1999), "Essentially Similar' Despite Being Different: The Squibb Case", BSLR

Kamperman Sanders, Anselm (1997), Unfair Competition Law, 1997, Clarendon Press, Oxford.

Kwa, Aileen (2001), "Dying for free trade", Resurgence, No. 131-132, July/August.

Ladas, Stephen, (1975), Patents, Trademarks, and Related Rights. National and International Protection, vol. III, Cambridge.

Lobato García-Miján, Manuel, (2000), Estudio sobre el fundamento jurídico de la protección de los secretos empresariales regulados en el artículo 266 de la Decisión Andina 486, FIFARMA.

Ollila, E. and Hamminki, E., (1996), "Secrecy in drug regulation", International Journal of Risk & Safety in Medicine, No. 9.

Priapantja, Priapantja, (2000), Trade Secret: How does this apply to drug registration data?, paper presented at "ASEAN Workshop on the TRIPS Agreement and its Impact on Pharmaceuticals", Department of Health and World Health Organization, Jakarta, 24 May 2000.

Raggett, Tom, (1996), GATT and patent reform. The global strengthening of patent protection and the implications for the pharmaceutical industry, Financial Times Management Reports, London.

Reichman, J. And Uhlir, Paul, (1999), "Database protection at the crossroads: recent developments and their impact on science and technology", Berkeley Technology Law Journal, vol. 14, No.2.

Trebilcock, Michael and Howse, Robert, (1999), The Regulation of International Trade, Routledge, London and New York.

UNCTAD, (1996), The TRIPS Agreement and developing Countries, UNCTAD/ITE/1, New York and Geneva.

Watal, Jayashree, (2001), Intellectual Property Rights in the WTO and Developing Countries, Kluwer Law International, The Hague/London/Boston.

WHO, (2000), The TRIPS Agreement and Pharmaceuticals. Report of an ASEAN Workshop on the TRIPS Agreement and its Impact on Pharmaceuticals, Jakarta, 2-4 May 2000.

WIPO, (1996), Model Provisions on Protection Against Unfair Competition, Geneva.